| Acute Limb Ischemia |
2 |
| Occulsion Types, Duration and Characteristics |
2 |
| Risk Factors |
2 |
| Four-Yer Event-Free Survival - IC, CLI and ALI |
3 |
| Percentage of Acute Limb Ischemia Caused by Thrombosis and Embolism |
3 |
| Locations of Thrombi and Emboli |
4 |
| Specific Risk Factors for Acute Limb Ischemia By Cause |
4 |
| Clinical Classification of Acute Limb Ischemia |
7 |
| Consequences of ALI |
8 |
| Cause of Death |
8 |
| Amputation Rates and Duration of Ischemia |
9 |
| ALI Survivors - Two-Year Outcome |
9 |
| Five-Year All-Cause Mortality for ALI and Selected Diseases |
10 |
| 30-Day Mortality ALI, Stroke and MI |
10 |
| 30-Day Consequences of ALI, AMI and Stroke |
11 |
| Co-Morbidities |
13 |
| ALI Treatments |
14 |
| Surgical Approaches |
15 |
| Thromboembolectomy Catheters |
15 |
| Bypass Graft Thrombolysis - Factors Associated with Favorable Outcomes |
16 |
| Surgery - Limb Salvage and Mortality |
16 |
| Complications of Survery |
17 |
| Advantages of Thrombolysis |
19 |
| Disadvantages of Thrombolysis |
19 |
| Thrombolysis - 30-Day Clinical Outcomes |
20 |
| Thrombolysis - Factors That Influence Amputation-Free Survival |
20 |
| Thrombolysis - Factors Associated With Higher Mortality |
21 |
| Complications of Thrombolysis |
21 |
| FDA-Approved Plasminogen Activators |
22 |
| Fibrin Specificity of Thrombolytic Drugs |
25 |
| Thrombolysis-Limitatons of Plasminogen Activators |
25 |
| Platelet Activation |
26 |
| Plasminogen Activators - Comparison of Efficacy and Safety |
28 |
| Thrombolysis Compared to Surgery |
31 |
| GP IIb/IIIa Inhibitors and Thrombolytics Combined - Potential Advantages |
33 |
| FDA-Approved GP IIb/IIIa Inhibitors |
33 |
| Comparison of GP IIb/IIIa Inhibitors |
39 |
| Characteristics of Alfimeprase |
43 |
| NAPA-1 Safety Results |
44 |
| Thrombolytic Infusion Catheters and Manufacturers |
46 |
| FDA-Approved Percutaneous Mechanical Thrombectomy Devices |
47 |
| PMT Limitations |
48 |
| PMT Complications |
48 |
| AngioJet in ALI - Mortality and Amputation at 30 Days |
53 |
| AngioJet in ALI - Complications |
54 |
| Hydrolyser in ALI - Mortality and Amputation at 30 Days |
55 |
| Ultrasound Enhanced Thrombolysis |
57 |
| Surgery, Thrombolysis, AngioJet PMT and Power Pulse Spray |
70 |
| Cost Comparison of Amputation and Revascularization* |
71 |
| Estimated Number of Procedures By ICD-9 Code - 2002 |
76 |
| 2000-2020 - Estimated Number of ALI Patients* |
79 |
| Number of ALI Patients Requiring Primary Therapy, Revision Therapy and Total Number of Procedures -2000-2020 |
82 |
| 2000-2020 - ALI Market Value |
84 |
| 2004 - Estimated Number of ALI Cases by Cause |
85 |
| 2000-2020 Estimated Number of ALI Cases Due to Thrombosis |
86 |
| 2000-2020 - Estimated Number of ALI Cases Due to Embolization |
87 |
| Estimated Percentage of ALI Patients By Clinical Classification |
88 |
| 2004 - Estimated Number of ALI Patients by Clinical Classification |
88 |
| 2000-2020 - Estimated Number of ALI Patients By Clinical Classification |
89 |
| Recommended Initial Therapy By Clinical Classification |
90 |
| 2005 - Primary Market Potential Based on Current Recommended Initial Therapy |
91 |
| 2000-2020 - Number of SVS III Patients Presenting Early and Late |
92 |
| 2000-2020 - Primary Market for Currently Approved Thrombolytics |
93 |
| 2000-2020 - Primary Market for New Safer Thrombolytics |
94 |
| 2000-2020 - Primary Market for Currently Approved PMT Devices |
96 |
| 2000-2020 - Primary Market for New Endovascular Devices |
97 |
| 2000-2020 - Primary Market for GP IIb/IIIa Inhibitors |
98 |
| 2000-2020 - Primary Market for Surgical Thromboembolectomy |
99 |
